Immutep Expands Part B of TACTI-002 Study
05 mars 2021 08h00 HE
|
Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
04 mars 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes,...
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
11 déc. 2020 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...
Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
04 déc. 2020 16h17 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the passing of the two...
Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
01 déc. 2020 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will...
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
09 nov. 2020 16h10 HE
|
Immutep Limited
Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release...
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
09 nov. 2020 08h00 HE
|
Galectin Therapeutics Inc.
Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role – Board Adds Two New Highly Accomplished Professionals NORCROSS, Ga., Nov. 09, 2020 ...
Correction: Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
06 nov. 2020 02h34 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade The Non-Small Cell Lung Cancer Pipeline...
Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
02 nov. 2020 10h17 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade The Non-Small Cell Lung Cancer Pipeline...
Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
29 sept. 2020 12h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host...